Literature DB >> 12505537

Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.

Nissar A Darmani1, Laura J Sim-Selley, Billy R Martin, Jano J Janoyan, Jennifer L Crim, Bavita Parekh, Christopher S Breivogel.   

Abstract

Dibenzopyran (Delta(9)-tetrahydrocannabinol) and aminoalkylindole [R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrolol[1,2,3-de]-1,4-benzoxazin-yl]-(1-naphthalenyl) methanone mesylate; (WIN55,212-2)] cannabinoids suppress vomiting produced by cisplatin via cannabinoid CB(1) receptors. This study investigates the antiemetic potential of the "nonclassical" cannabinoid CP55,940 [1alpha,2beta-(R)-5alpha]-(-)-5-(1,1-dimethyl)-2-[5-hydroxy-2-(3-hydroxypropyl) cyclohexyl-phenol] against cisplatin-induced vomiting and assesses the presence and functionality of cannabinoid CB(1) receptors in the least shrew (Cryptotis parva) brain. CP55,940 (0.025-0.3 mg/kg) reduced both the frequency of cisplatin-induced emesis (ID(50)=0.025 mg/kg) and the percentage of shrews vomiting (ID(50)=0.09 mg/kg). CP55,940 also suppressed shrew motor behaviors (ID(50)=0.06- 0.21 mg/kg) at such doses. The antiemetic and motor-suppressant actions of CP55,940 were countered by SR141716A [N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide], indicating both effects are cannabinoid CB(1) receptor-mediated. Autoradiographic studies with [3H]-SR141716A and [35S]-GTPgammaS binding revealed that the distribution of the cannabinoid CB(1) receptor and its activation pattern are similar to rodent brain and significant levels are present in brain loci (e.g., nucleus tractus solitarius (NTS)) that control emesis. The affinity rank order of structurally diverse cannabinoid ligands for cannabinoid CB(1) receptor in shrew brain is similar to rodent brain: HU-210=CP55,940=SR141716A>/=WIN55,212-2>/=delta-9-tetrahydrocannabinol>methanandamide=HU-211=cannabidiol=2-arachidonoylglycerol. This affinity order is also similar and is highly correlated to the cannabinoid EC(50) potency rank order for GTPgammaS stimulation except WIN55,212-2 and delta-9-tetrahydrocannabinol potency order were reversed. The affinity and the potency rank order of tested cannabinoids were significantly correlated with their antiemetic ID(50) potency order against cisplatin-induced vomiting (CP55,940>WIN55,212-2=delta-9-tetrahydrocannabinol) as well as emesis produced by 2-arachidonoylglycerol or SR141716A (CP55,940>WIN55,212-2>delta-9-tetrahydrocannabinol).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12505537     DOI: 10.1016/s0014-2999(02)02815-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

Review 1.  Involvement of cannabinoid receptors in gut motility and visceral perception.

Authors:  Pamela J Hornby; Stephen M Prouty
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

Review 2.  Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review.

Authors:  Cecilia J Sorensen; Kristen DeSanto; Laura Borgelt; Kristina T Phillips; Andrew A Monte
Journal:  J Med Toxicol       Date:  2016-12-20

3.  Δ9-THC and related cannabinoids suppress substance P- induced neurokinin NK1-receptor-mediated vomiting via activation of cannabinoid CB1 receptor.

Authors:  Nissar A Darmani; Louiza Belkacemi; Weixia Zhong
Journal:  Eur J Pharmacol       Date:  2019-11-15       Impact factor: 4.432

4.  Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling.

Authors:  Teodora Georgieva; Savitha Devanathan; Dagmar Stropova; Chad K Park; Zdzislaw Salamon; Gordon Tollin; Victor J Hruby; William R Roeske; Henry I Yamamura; Eva Varga
Journal:  Eur J Pharmacol       Date:  2007-11-28       Impact factor: 4.432

5.  Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.

Authors:  Nissar A Darmani; Jano J Janoyan; Jennifer Crim; Juan Ramirez
Journal:  Eur J Pharmacol       Date:  2007-02-16       Impact factor: 4.432

Review 6.  Medical Use of Cannabinoids.

Authors:  Ana Isabel Fraguas-Sánchez; Ana Isabel Torres-Suárez
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

7.  Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system.

Authors:  Keith A Sharkey; Nissar A Darmani; Linda A Parker
Journal:  Eur J Pharmacol       Date:  2013-11-01       Impact factor: 4.432

Review 8.  Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting.

Authors:  Nissar A Darmani
Journal:  Pharmaceuticals (Basel)       Date:  2010-09-03

Review 9.  Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC.

Authors:  Jackson M J Oultram; Joseph L Pegler; Timothy A Bowser; Luke J Ney; Andrew L Eamens; Christopher P L Grof
Journal:  Biomedicines       Date:  2021-02-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.